Endo Pharmaceuticals (NASDAQ:ENDP) faces a drug shortage risk for some of its opiates, such as Percocet, as Novartis Consumer Group sorts out a mix-up that could cause extended release opiates for ...
We are maintaining our Neutral stance on Endo Pharmaceuticals (NasdaqGS:ENDP - News) with a target price of $34.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and ...
MALVERN, Pa., June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International ...
Looking at all of its recent acquisitions, you might think Endo Pharmaceutical's (NMS:ENDP) business model echoes another firm's. One like Johnson & Johnson's (NYSE:JNJ - News). That makes sense. Endo ...
All told, the drugmakers project that the combined company will generate $3.6 billion in 2025 revenue, plus earnings of $1.2 billion. (Gajus/iStock/Getty Images Plus) Having spent the better part of ...
Endo Pharmaceuticals (NASDAQ: ENDP) has received approval from the Food and Drug Administration for its drug Felodipine extended-release tablets, a generic version of AstraZeneca‘s (NYSE: AZN) drug, ...
Endo offers $4.85 per HealthTronics share Says deal to add to 2010 adj shr FY forecast above Street view Endo Pharma shares down 3 pct HealthTronics shares up 33 pct May 5 (Reuters) - Endo ...
MALVERN, Pa., March 11, 2025 /CNW/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results